ES-FSG-FO-00218-WD

Review Girard 67. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J. Neurooncol. 99(2), 283–286 (2010). 68. Deng Y, Feng W, Wu J et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol. Clin. Oncol. 2(1), 116–120 (2014). 69. Hata A, Kaji R, Fujita S, Katakami N. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J. Thorac. Oncol. 6(3), 653–654 (2011). 70. Lee E, Keam B, Kim DW et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J. Thorac. Oncol. 8(8), 1069–1074 (2013). 71. Togashi Y, Masago K, Masuda S et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother. Pharmacol. 70(3), 399–405 (2012). 72. Zhuang H, Yuan Z, Wang J, Zhao L, Pang Q, Wang P. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des. Devel. Ther. 7, 1179–1186 (2013). 73. Zeng YD, Zhang L, Liao H et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac. J. Cancer Prev. 13(3), 909–914 (2012). 74. Zhu Q, Sun Y, Cui Y et al. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC). Oncotarget 8(8), 13304–13311 (2017). 75. Schuler M, Wu YL, Hirsh V et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J. Thorac. Oncol. 11(3), 380–390 (2016). • Prespecified subgroup analysis of LUX-Lung 3 and 6 trials that showed afatinib prolonged PFS versus chemotherapy in patients with EGFR mutation-positive NSCLC and asymptomatic brain metastases. 76. Hirsh V, Yang JC-H, Tan EH et al. First-line afatinib versus gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): patient-reported outcomes and impact of dose modifications on efficacy and adverse events. J. Clin. Oncol. 34(Suppl. 15), abstract 9046 (2016). 77. Yang JC, Sequist LV, Zhou C et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann. Oncol. 27(11), 2103–2110 (2016). • Post hoc analysis of the LUX-Lung 3 and 6 trials showing that tolerability-guided dose adjustment reduced the frequency and intensity of adverse events associated with afatinib without compromising efficacy. 78. Ramalingam S, Reungwetwattana T, Chewaskulyong B et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Ann. Oncol. 28(Suppl. 5), v605–v649 (2017). 79. Peters S, Zimmermann S, Adjei AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat. Rev. 40(8), 917–926 (2014). 80. AstraZeneca. TAGRISSO product monograph. (2016). www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/TAGRISSO%20-%20Product-Monograph.pdf 81. European Medicines Agency. TAGRISSO summary of product characteristics. (2016). www.ema.europa.eu/docs/en GB/document library/EPAR - Product Information/human/004124/WC500202022.pdf 82. Corral J, Park K, Yang JC-H et al. Afatinib versus gefitinib in patients with EGFR mutation-positive (EGFRm + ) NSCLC: updated overall survival data from the Phase IIb trial LUX-Lung 7. Ann. Oncol. 28(Suppl. 2), ii28–ii51 (2017). 83. Conforti F, Catania C, Toffalorio F et al. EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung. Lung Cancer 81(3), 440–444 (2013). 10.2217/fon-2017-0636 Future Oncol. (Epub ahead of print) future science group

RkJQdWJsaXNoZXIy MzQyNTUz